Argent Biopharma Ltd · ASX:RGT
Argent Biopharma — MGC Pharmaceuticals — Investor Presentation (October 2019)
26 slides from Argent Biopharma's investor presentation, October 2019
Slide 1: Company Presentation October 2019
OVERVIEW MARKET APPENDIX Leading The Way in Phytocannabinoid Derived Medicines with a Seed-to-Pharmacy Strategy Company Presentation October 2019
Slide 2: Disclaimer
Disclaimer OVERVIEW This presentation has been prepared by MGC Pharmaceuticals Limited (“Company”). It Future matters does not purport to contain all the information that a prospective investor may require This presentation contains reference to certain intentions, expectations, future plans, in con
Slide 3: Investment Highlights
Investment Highlights OVERVIEW MGC Pharma is an industry leading, European bio-pharma company supplying GMP Phytocannabinoid derived medicines to patients globally Authorised products targeting medical conditions: epilepsy and dementia MARKET Additional targeted products in development pipeline
Slide 4: Global Footprint
Global Footprint OVERVIEW Slovenia: Primary Research Base United Kingdom: • Botanical and Pharma research base • European Corporate Headquarters • Manufacturing centre with EU GMP • Planned LSE Standard dual listing 2019 certification MARKET Malta: Primary Operation Base • Main EU production facilit
Slide 5: In Numbers
In Numbers OVERVIEW Established EU-GMP licence approved leader in the cannabis space 2 Over 15 3 MARKET Operations Years Experience in Developed Facilities Medical Cannabis Research Products Malta & Slovenia R&D team backed by extensive And pipeline of potential industry experience products in devel
Slide 6: Global Market
Global Market OVERVIEW Estimated cannabis for Cannabis based medicine Europe to be largest Nov 1st 2018 medicinal use value sales to increase by medical cannabis market. UK legalised prescription MARKET £47billion 182% Total healthcare spend: of medical cannabis in 2028 2016-2020 £2.1t products APPE
Slide 7: Board of Directors
Board of Directors OVERVIEW Highly qualified team with over 15 years of relevant experience MARKET Roby Zomer Brett Mitchell Nativ Segev Dr. Stephen Parker Dr. Ross Walker Managing Director, CEO & Executive Chairman Director, Head of Business Director & Chairman of Audit, Director & Founder Strategy
Slide 8: Scientific Team
Scientific Team OVERVIEW Leading experts in the medical cannabis space with unparalleled expertise MARKET Dr. Jonny Grunfeld Professor Uri Kramer Professor David Professor Stane Srčič Professor Head of Neurology product development Neubauer Nadya Lisovoder Certified in Israel, with clinical One of t
Slide 9: Vision
Vision OVERVIEW Building an industry leading global bio-pharma company, With: Cost effective, Compliant, Affordable medicine 1. Engage in continuous research to maintain cutting edge position– Botanical and Pharmaceutical for the highest regulatory compliance medicines (EMA) MARKET 2. Advance commer
Slide 10: Company Snapshot
Company Snapshot OVERVIEW MGC Pharma is at the forefront of Global Phytocannabinoid derived medicines FIRST PRODUCT TO MARKET BEST-IN-CLASS MANUFACTURING • CannEpil® is a phytocannabinoid product aimed • EU-GMP certification granted for production of for drug-resistant epilepsy phytocannabinoid base
Slide 11: Seed to Pharmacy Manufacturing
Seed to Pharmacy Manufacturing OVERVIEW Creation and commercialisation of Phytocannabinoid derived products through a vertically integrated model utilising in house R&D capability Global Operation New Centralised EU Hub • Multi-National base • Maltese Facility to become primary • EU-GMP certified fa
Slide 12: MGC Research & Development
MGC Research & Development OVERVIEW 3 research arms based on medical experience and large data collections Lead by Ass. Prof Nitin Lead by Prof Uri Kramer Mantri (RMIT) Epilepsy Anti-Inflammatory Dementia Anti-Bacterial Cerebral Palsy MARKET Neurology Oncology Autoimmune APPENDIX Lead by Dr. Jonatha
Slide 13: Products – Pharmaceuticals
Products – Pharmaceuticals OVERVIEW Phase I Targeting specific medical conditions such as epilepsy and dementia Phase II Dementia IBS • Oral oil solution to Epilepsy • Oral spray utilising a • Bioactive Capsule for treat seizures specific THC:CBD symptoms of Crohn’s MARKET associated with drug ratio
Slide 14: CannEpil®
CannEpil® OVERVIEW CannEpil® is a Phytocannabinoid derived IMP used as a treatment for refractory epilepsy ® • Authorized to prescribe in Australia and CannEpil® is an oral oil solution of UK through early patient access schemes cannabidiol (CBD) and (-)- trans-Δ9- Neurological Disorders MARKET • Ov
Slide 15: CogniCann™
CogniCann™ OVERVIEW CogniCann™ is MGC second Phytocannabinoid derived IMP designed to improve dementia and Alzheimer’s patients quality of life ™ • Authorized to prescribe in Australia and CogniCann™ is a sublingual spray of UK through Early Patient Access Scheme cannabidiol (CBD) and (-)- trans-Δ9-
Slide 16: Research and Development
Research and Development OVERVIEW • Developing medicines that leverage its proprietary medical cannabis formula through successful clinical trials in Europe, Australia • This will enable future medical product sales across the EU, Australia and other geographies, following the requisite legal and re
Slide 17: Strategic Partnership with RMIT
Strategic Partnership with RMIT OVERVIEW MGC Pharma and RMIT developing CannaHub, a digital research hub for the application of Phytocannabinoid derived medicines including the International Library of Cannabinoids (ILC) INTERNATIONAL LIBRARY OF CANNABINOIDS • ILC is the World’s first library of can
Slide 18: Cannabinoids and Brain Cancers
Cannabinoids and Brain Cancers OVERVIEW Pre-clinical research conducted in collaboration with the National Institute of Biology and University Medical Centre Ljubljana Research highlighted the positive impact of using specific cannabinoid formulations in the treatment of glioblastoma, the most aggre
Slide 19: Cultivation & Production
Cultivation & Production OVERVIEW CULTIVATION PRODUCTION • Active engagement with multiple cultivation sites to meet • Production of high quality pharmaceutical products to be used increasing global demand as part of a prescribed medical treatment plan • Specialised controlled cultivation also under
Slide 20: Commercial Production: Malta – a Centralised Hub
Commercial Production: Malta – a Centralised Hub OVERVIEW Establishing a fully vertically integrated medical cannabis “Seed to Pharmacy” operation in the EU Signed long-term lease on 6,000m2 site for full medical Medical Cannabis legalised in Malta – provides direct access cannabis facility providin
Slide 21: Malta facility – Architectural Design of Malta Hub
Malta facility – Architectural Design of Malta Hub OVERVIEW Front view MARKET Side view APPENDIX MGC Pharma | Company Presentation 20
Slide 22: Key Wholesaler Partner
Key Wholesaler Partner OVERVIEW LENIS – A FULL-SERVICE PHARMACEUTICAL DISTRIBUTOR Lenis specializes in the distribution of unlicensed drugs and niche therapeutic areas (licensed in the source country but not in the destination country). This includes: • New drugs not yet approved in a country • Disc
Slide 23: Key Distribution Partners
Key Distribution Partners OVERVIEW Extensive network in place providing access to hospitals, pharmacies and research institutions around the world AUSTRALIA SOUTH AMERICA EUROPE AFRICA ASIA MARKET Distributor with has a disruptive digital Distribution channels with a strong Health House specialist a
Slide 24: Strategic Milestones
Strategic Milestones OVERVIEW Achieving values over time as “Seed to Pharmacy” Bio-Pharma Company InCann Clinical CannEpil® vs euGMP Programme CBD Head-to- approved in MARKET Initiated Head Trial Malta Complete Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2019 2019 2020 2020 2020 2020 2021 2021 2021 2021 2022 A
Slide 25: Investment Case
Investment Case OVERVIEW Fully Integrated Model: Grow Develop Commercialise Built on Decades of Experience Technical team of globally recognised scientists and doctors Focussed Operations MARKET Core divisions: Research and Development Manufacturing and Distribution Strategically Located Operati
Slide 26: OVERVIEW APPENDIX
OVERVIEW https://mgcpharma.com.au/ MARKET @mgcpharamaceuticals @MGC_Pharma MGC Pharmaceuticals, Ltd. APPENDIX Financial PR: St Brides Partners (+44) 02072361177 info@stbridespartners.co.uk
MGC Pharmaceuticals — Investor Presentation (October 2019) on 6ix